| Document |
Document Title |
|
WO/2009/014610A2 |
The invention provides an efficient method for preparing 3-endo-(S- azabicyclo[3.2.1]oct-3-yl)benzamide by hydrogenation, under controlled conditions, of an amino-protected 3-(8-azabicyclo[3.2.1]oct-2-en-3-yl)benzamide intermediate in wh...
|
|
WO/2009/007115A1 |
Compounds of formula (I) wherein the substituents have the meanings assigned to them in claim 1, are useful as pesticides.
|
|
WO/2008/151677A1 |
Relates to a new polymorphic form of Granisetron base, Form I, to methods for obtaining thereof, to the method for obtaining Granisetron • HCl and its use for preparing pharmaceutical formulations. The Form I is characterized by the X-...
|
|
WO/2008/145504A2 |
The invention relates to a novel method for producing scopine esters of the general formula (1), wherein X -, R, R1 , R2 , R3, R4, R3',R4', R6 and R6'can have the meanings indicated in the claims and in the description.
|
|
WO/2008/143343A1 |
[PROBLEMS] To provide a novel mutilin derivative substituted at the 14-position which shows a potent and broad antibacterial function on gram-positive bacteria and gram-negative bacteria including various drug-resistant bacteria and is e...
|
|
WO/2008/138854A1 |
This invention relates to novel chromen-2-one derivatives useful as starting material for synthesis of pharmaceuticals. In other aspects the invention relates to a method of preparing the chromen-2- one derivatives of the invention..
|
|
WO/2008/132128A2 |
Process for the manufacture of UK- 427,857 ( Maraviroc ) which comprises a step wherein enantiopure (S)-3-amino-3-phenylpropan-1-ol is manufactured from a mixture of its enantiomers by crystallizing or precipitating from a solution conta...
|
|
WO/2008/125691A2 |
The invention relates to naphthalene carboxylic acid and isoquinoline carboxylic acid amides, and related compounds of formula (I) and their uses as pharmaceuticals.
|
|
WO/2008/117282A1 |
Provided is crystalline granisetron base form I and processes for producing crystalline granisetron base form I, which is suitable for preparing, e.g., granisetron salts such as, e.g., the hydrochloride salt. Also provided is a process f...
|
|
WO/2008/117229A1 |
The present invention relates to muscarinic receptor antagonists, which are useful, among other uses, for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors. T...
|
|
WO/2008/117871A1 |
Disclosed is a redox catalyst containing a compound represented by the formula (I) below or a derivative thereof. (In the formula, X1 and X2 independently represent a hydrogen atom, a halogen atom, an optionally substituted hydroxy group...
|
|
WO/2008/104584A1 |
The invention relates to a hydrochloride salt of (1R, 2R, 3S, 5S)-3-(3,4-dichlorophenyl)-2-[(methyloxy)methyl]-8-azabicycl
o[3.2.1]octane, uses of the salt as a medicament in the treatment inter alia of disorders of the central nervous s...
|
|
WO/2008/106159A1 |
The invention provides a crystalline sulfate salt of 3-endo-(8-{2-[cyclohexylmethyl-((S)-2,3-dihydroxy-propionyl)
amino]ethyl}-8-aza-bicyclo[3.2.1]oct-3-yl)benzamide or a solvate thereof. The invention also provides pharmaceutical compos...
|
|
WO/2008/106442A1 |
The present invention discloses the reactivity of ponytail ("PT") sulfonates as leaving groups in nucleophilic fluorination reactions. The results showed that using a pentafluorobenzenesulfonate precursor is a suitable leaving group for ...
|
|
WO/2008/104955A1 |
This present invention relates to muscarinic receptor antagonists of formula (I), which are useful, among other uses, for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscari...
|
|
WO/2008/101979A1 |
The present invention is related to quinoxaline compounds of Formula (I) in particular for the treatment of autoimmune disorders and/or inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, bacterial or viral infect...
|
|
WO/2008/101728A1 |
The invention relates to an improved one-stage method for producing azoniaspironortropine esters such as trospium chloride by reacting an endonortropine compound with an organic dihalogen compound and an α-hydroxycarboxylic acid in the ...
|
|
WO/2008/095821A1 |
The present invention relates to compounds of formula (I), wherein A and R1 to R4 are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prevention o...
|
|
WO/2008/092832A1 |
The invention relates to a method for producing ammonium hexafluorophosphates of general formula (1) wherein R1, R2, R3 and R4 are defined as in the claims and in the description, said novel ammonium hexafluorophosphates and to the use t...
|
|
WO/2008/092833A1 |
The invention relates to a novel method for producing scopinium salts of general formula (1) wherein Y- is defined as cited in the claims and in the description.
|
|
WO/2008/089852A1 |
The invention relates to a novel process for preparing tiotropium salts of the general formula (1), where X- can have the meanings given in the claims and in the description.
|
|
WO/2008/089201A2 |
The invention relates to Heterocyclic-Substituted Piperidine Compounds, compositions comprising an effective amount of a Heterocyclic-Substituted Piperidine Compound and methods to treat or prevent a condition, such as pain, comprising a...
|
|
WO/2008/083367A2 |
Polycyclic heteroaryl substituted triazoles and pharmaceutical compositions containing the compounds are disclosed as being useful in inhibiting the activity of the receptor protein tyrosine kinase Axl. Methods of using the compounds in ...
|
|
WO/2008/077555A2 |
The invention relates to 6-substituted isoquinoline and isochinolone derivatives of the formula (I) useful for the treatment and/or prevention of diseases associated with Rho-kinase and/or Rho-kinase mediated phosphorylation of myosin li...
|
|
WO/2008/074703A1 |
Compounds of the formula (I) or pharmaceutically acceptable salts thereof, wherein m, n, Ar, R1, R2, Ra and Rb are defined herein. Also provided are pharmaceutical compositions, methods of using, and methods of preparing the compounds.
|
|
WO/2008/074797A1 |
This invention relates to novel chromen-2-one derivatives of Formula (I) useful as monoamine neurotransmitter re-uptake inhibitors. In other aspects the invention relates to the use of these compounds in a method for therapy and to pharm...
|
|
WO2008058096A9 |
The invention relates to compounds that are azaadamantane derivatives, particularly ether- or amine-substituted azaadamantane derivatives and salts and prodrugs thereof, compositions comprising such compounds, methods of using such compo...
|
|
WO/2008/074798A1 |
This invention relates to novel chromen-2-one derivatives of Formula (I) useful as monoamine neurotransmitter re-uptake inhibitors. In other aspects the invention relates to the use of these compounds in a method for therapy and to pharm...
|
|
WO/2008/077103A1 |
Disclosed herein are substituted 8-azabicyclo[3.2.1]octane-based anti-infective agents of Formula I, processes of preparation thereof, pharmaceutical compositions thereof, and methods of use thereof.
|
|
WO/2008/063600A2 |
This invention relates to novel triazolyl tropane derivatives of the formula (II), their acceptable acid addition salts, solvates, hydrates and polymorphs thereof. The invention also provides compositions comprising a compound of this in...
|
|
WO/2008/059349A1 |
The invention relates to a one-step [18F]radiolabelling process of tropanamine derivatives which are useful for imaging the neuronal dopamine transporter (DAT) with Positron Emission Tomography (PET).
|
|
WO/2008/058968A1 |
The invention relates to a new crystalline form of tiotropium bromide, processes for preparing it and its use for preparing a pharmaceutical composition for the treatment of respiratory complaints, particularly for the treatment of COPD ...
|
|
WO/2008/026658A1 |
Disclosed is an N-pyridylpiperidine compound represented by the following general formula (1). (In the formula, R1 represents a halogen atom, a C1-4 haloalkyl group, a cyano group, a nitro group or a C1-4 alkoxycarbonyl group; R2, R3, R4...
|
|
WO/2008/019372A2 |
Compounds of Formulae (I), (II) and (III): are disclosed as 5-HT3 inhibitors. The compounds are useful in treating CINV, IBS-D and other diseases and conditions.
|
|
WO/2008/019363A2 |
A genus of 2-alkylbenzoxazole carboxamides are disclosed as 5-HT3 inhibitors. Those compounds are useful in treating CINV, IBS-D and other diseases and conditions.
|
|
WO/2008/008376A2 |
The invention is directed to improved processes for preparing Tiotropium bromide using scopine salts.
|
|
WO/2008/003702A2 |
Compounds that interact with the histamine H4 receptor, and which may be useful for treating or preventing disorders and conditions mediated by the histamine H4 receptor, e.g. inflammation, are of formula (I) wherein Q is CR1 or N; X is ...
|
|
WO/2007/143847A1 |
Compounds according to formula (I): (Insert formula from claim 1 here) wherein R1, R2, R3, n and X are defined as defined herein, and the pharmaceutically acceptable salts, hydrates and solvates thereof, are useful for the modulation of ...
|
|
WO/2007/141504A1 |
A series of 5,6-dihydro-1-benzothiophen-7(4H)-one derivatives, and analogues thereof, which are substituted in the 2-position by an optionally substituted morpholin-4-yl moiety, being selective inhibitors of PI3 kinase enzymes, are accor...
|
|
WO/2007/137030A2 |
The invention relates to fused bicycloheterocycle substituted azabicyclic alkane derivatives of formula (I), or a pharmaceutically acceptable salt, ester, amid, or prodrug thereof, wherein n is 1, 2 or 3; A is N or N+-O-; R is hydrogen, ...
|
|
WO/2007/116313A2 |
The present invention provides compounds of formula (I) wherein R1 to R6 and m are as defined hereinabove. The compounds of the present invention are modulators, especially antagonists, of the activity of chemokine CCR5 receptors. Modula...
|
|
WO/2007/111323A1 |
Discloses is a pharmaceutical agent comprising an ureide derivative represented by the formula: or a pharmaceutically acceptable salt thereof as an active ingredient. The ureide derivative or the pharmaceutically acceptable salt thereof ...
|
|
WO2006076317A9 |
Disclosed herein is a novel class of aminophenyl compounds having the structure (I) wherein R1 is cyano or nitro and ring A is a bi- or tricyclic bridged heterocycle and to their use as modulators of androgen receptor for the treatment o...
|
|
WO2007081889A9 |
The present invention provides an improved process for the preparation of Dolasetron salts, in particularly Oolasetron mesylate (DLS-MSOH-H2O). Also provided are intermediates for the process and methods of preparing the intermediates.
|
|
WO/2007/104652A2 |
Non-peptidic renin inhibitors nitroderivatives of general formula (I): A1-(Xa-ONO2)j 5 (I) having wider pharmacological activity and enhanced tolerability. They can be employed for treating or preventing cardiovascular, renal and chronic...
|
|
WO/2007/103187A2 |
The invention provides novel 8-azabicyclo[3.2.1]octane compounds of formula (I) wherein R1, R2, R3, A, and G are defined in the specification, or a pharmaceutically-acceptable salt or solvate thereof, that are antagonists at the mu opioi...
|
|
WO/2007/100851A1 |
The invention provides a compound of formula (I) wherein R1-R6, X, Y, and B have any of the values described herein, as well as salts of such compounds, compositions comprising such compounds, and therapeutic methods that comprise the ad...
|
|
WO/2007/097976A1 |
The invention provides 8-azabicyclo[3.2.1]octyl intermediates of formula (I): useful for the preparation of 5-HT4 receptor agonist compounds. The invention also provides processes for the preparation of such useful intermediates.
|
|
WO/2007/093366A1 |
The invention relates to aminoalcohol-substituted aryldihydroisoquinolinones and their derivatives, and their physiologically tolerated salts and physiologically functional derivatives, their preparation, medicaments comprising at least ...
|
|
WO/2007/093604A1 |
This invention relates to novel chromen-2-one derivatives of formula (I) useful as monoamine neurotransmitter re-uptake inhibitors. In other aspects the invention relates to the use of these compounds in a method for therapy and to pharm...
|
